Synaptic activity protects neurons

Chatter between neurons can help protect them from the ravages of free radical damage, according to a linkurl:report;http://www.nature.com/neuro/journal/vaop/ncurrent/abs/nn2071.html published today (Mar 23) in __Nature__. Free radical, or oxidative, damage besets neurons as they linkurl:age;http://www.the-scientist.com/article/display/13036/ normally or degenerate due to chronic disorders, such as Alzheimer's or Parkinson's, or in acute events, such as strokes. University of Edinburgh neurosci

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
Chatter between neurons can help protect them from the ravages of free radical damage, according to a linkurl:report;http://www.nature.com/neuro/journal/vaop/ncurrent/abs/nn2071.html published today (Mar 23) in __Nature__. Free radical, or oxidative, damage besets neurons as they linkurl:age;http://www.the-scientist.com/article/display/13036/ normally or degenerate due to chronic disorders, such as Alzheimer's or Parkinson's, or in acute events, such as strokes. University of Edinburgh neuroscientist linkurl:Giles Hardingham;http://www.cnr.ed.ac.uk/links/gharding.htm and colleagues found that N-methyl-D-aspartate (NMDA) receptors, whose activation is critical to synaptic transmission, modulate a web of antioxidant pathways, preventing or reversing the effects of oxidative damage on nerve cells. "This was the first time that it was seen that synaptic activity can regulate the vulnerability of neurons to oxidative stress," Hardingham told __The Scientist__. Hardingham and his team suppressed normal NMDA receptor activity in rat and mouse neurons and tracked cell survival and the downstream transcription of genes involved in oxidation-reduction pathways. They found that NMDA receptor activity enhances the activity of two antioxidant proteins, thioredoxin and peroxiredoxin, while promoting resistance to oxidative stress by downregulating __Txnip__, a thioredoxin inhibitor. "It seems that the synaptic activity tells [nerve] cells how to protect one another," Burnham Institute for Medical Research neuroscientist linkurl:Stuart Lipton;http://www.burnham.org/default.asp?contentID=242 told __The Scientist__. linkurl:Lipton,;http://www.the-scientist.com/article/display/17816/ also a neurologist, said that Hardingham's study gave unprecedented insight into how synaptic activity influences the intricate network of antioxidant pathways in neurons. "Nobody had any idea that these post-transcriptional modifications were occurring," said Lipton, who was not involved with the study. Hardingham and his team also showed in vivo that these protective pathways were compromised in instances of acute neuronal damage, such as stroke. Because oxidative damage is known to be a feature of other neurological disorders, the same enzymatic systems may be important in the progression of Alzheimer's disease and other similar diseases. "Obviously it's a possibility," Hardingham said, "but it remains to be seen if life-long patterns of synaptic activity might influence [a neuron's] accumulation of oxidative damage in vivo over a number of years." Hardingham says that his group is now trying to identify small molecules that can modulate antioxidant pathways in neurons to prevent or reverse oxidative stress. This research could lead to drugs that reverse the symptoms of stroke or protect people from long-term neurological damage. "It's really very early days in this study, but it's promising for sure," Hardingham said. Lipton has already developed a drug - linkurl:memantine;http://www.memantine.com/en/ - that allows synaptic NMDA receptor activity but blocks extra-synaptic NMDA receptor activity, which is known to contribute to the progression of Alzheimer's disease. Lipton said that Hardingham's study provides further support for the mechanism at play behind memantine's effectiveness. "Now we understand better why [the drug] works," Lipton said. Memantine, under the trade name Namenda, gained FDA linkurl:approval;http://www.the-scientist.com/article/display/15018/ in 2003 for treating Alzheimer's disease.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo